Genetic Factors in Atherosclerosis
|ClinicalTrials.gov Identifier: NCT00359307|
Recruitment Status : Completed
First Posted : August 2, 2006
Last Update Posted : June 20, 2018
The purpose of this study is to identify genes associated with certain risk factors for atherosclerosis (hardening of the arteries) and its consequences, such as development of coronary artery disease, heart attack, other blood vessel disease and stroke.
People enrolled in the Framingham Heart Study in Framingham, Massachusetts, are eligible to participate in this study. They will undergo a medical history, including review of their medical records and a family history; evaluation of memory and mood; breathing test and electrocardiogram (EKG); blood and urine tests, including blood sample collection for DNA (genetic) testing; evaluation of gait (walking), balance and hand grip strength; and hearing test. They will also fill out questionnaires on their eating habits and general health.
Any patients who may suffer a stroke during the study will be examined during their hospitalization and at 3, 6, 12, and 24 months after the stroke. This examination includes a neurological evaluation, assessment of ability to perform daily living tasks and, possibly, magnetic resonance imaging (MRI) of the brain, a test that uses a strong magnetic field and radio waves to produce pictures of the brain.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||1888 participants|
|Official Title:||Chemokine System Polymorphisms and Risk of Atherosclerosis (CAD)|
|Study Start Date :||June 8, 2000|
|Study Completion Date :||March 21, 2013|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00359307
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||David H McDermott, M.D.||National Institute of Allergy and Infectious Diseases (NIAID)|